910605-22-0

Upstream product

• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 
• 148583-58-8 4-(2-isopropoxy-phenyl)-piperidine 
• 701-07-5 1-bromo-2-isopropoxybenzene 
• 95-56-7 2-hydroxybromobenzene 
• 910605-23-1 {4-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexyl}-carbamic acid tert-butyl ester 
• 174822-94-7 C₁₉H₂₉NO₃ 
• 946605-56-7 C₁₉H₂₉NO₄ 
• 910605-24-2 4-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexylamine 
• 23095-31-0 3,4-dimethoxybenzene-1-sulfonyl chloride 

Relevant academic research and scientific papers

(Phenylpiperidinyl)cyclohexylsulfonamides: Development of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)

Although α1 adrenergic receptor blockers can be very effective for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), their usage is limited by CV-related side-effects that are caused by the subtype non-selec

Aminocyclohexylsulfonamides: Discovery of metabolically stable α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)

Benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) can be effectively treated by α1 adrenergic receptor antagonists, but these drugs also produce side effects that are related to their subtype non-selective nature. To overcome